Summary
We are delighted to share that the ICM - Institut du Cancer de Montpellier was authorized by the French Data Protection Authority (CNIL) to conduct APAD-ECO study.
The CNIL granted authorization to conduct a medico-economic study on the effects of physical activity in women treated for breast cancer on April, 19th. This groundbreaking study involves combining data from two clinical trials with that of the Caisse nationale de l’Assurance Maladie, covering the period from 2009 to 2022.
The study aims to assess the long-term impacts of physical activity in patients who have undergone treatment for breast cancer.
We are proud to have contributed to this project by providing the ICM - Institut du Cancer de Montpellier with a compliant Data Protection Impact Assessment (DPIA), a crucial step in obtaining CNIL approval.
FAQs
Our frequently questions
Find out how iliomad can help your company.
Only visible in production
EDPB Anonymisation Guidelines 2026 and Clinical Trial Data: What Life Sciences Organisations Must Know
EDPB Guidelines 02/2026 on anonymisation set new standards for clinical trial data. Learn the three-criteria test, enforcement lessons and compliance steps. iliomad.
AI Triage, Biopharma Workbenches and Crumbling Data Bridges: iliomad Weekly Digest
NHS AI triage, Anthropic Claude Science, medical AI privacy risks, MHRA GxP guidance, EDPS ADM checklist and the EU-US data transfer threat explained.
Human Intervention in Automated Decision-Making: What the EDPS Checklist Means for Life Sciences
The EDPS checklist on human intervention in automated decision-making carries direct implications for GDPR clinical trials. Learn what effective oversight requires.
